این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
The Journal of Tehran University Heart Center، جلد ۱۹، شماره ۴، صفحات ۲۵۶-۲۶۳
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Efficacy of the Optimal Dosage of Lisinopril in Inhibiting Myofibroblast Differentiation for Attenuating Rheumatic Heart Disease Progression: An in Vitro Study
چکیده انگلیسی مقاله Background: Rheumatic heart disease (RHD) is exacerbated by chronic inflammation that stimulates the release of proinflammatory cytokines, most notably transforming growth factor-beta 1 (TGF-β1), which promotes myofibroblast differentiation. This study aims to determine the optimal dosage of Lisinopril, an angiotensin-converting enzyme inhibitor, for mitigating the fibrotic changes associated with RHD. Methods: This in vitro, posttest-only control group study involved obtaining valvular interstitial cells from the heart valves of 25 male New Zealand rabbits (Oryctolagus cuniculus). Valvular interstitial cells were divided into 5 groups: a control group exposed to TGF-β1, and 4 experimental groups exposed to various Lisinopril doses (1 µM, 10 µM, and 100 µM) in addition to TGF-β1. The effect of Lisinopril on myofibroblast differentiation was assessed by measuring alpha-smooth muscle actin (αSMA) expression through immunocytochemical methods. Statistical significance was determined using an independent T-test with a P value of less than 0.050. Results: Independent T-tests conducted on 25 male Oryctolagus cuniculus demonstrated significantly lower αSMA expression in the groups treated with various Lisinopril doses (1 µM, 10 µM, and 100 µM) compared with the TGF-β1-induced control group (P<0.050). The most significant reduction in αSMA expression was observed in the group treated with the highest Lisinopril dose of 100 µM. Conclusion: Lisinopril demonstrates a significant ability to inhibit TGF-β1-induced myofibroblast differentiation in rabbit valve interstitial cells, with the 100 µM dose proving most effective. These results suggest that Lisinopril may have the potential to curb RHD progression, warranting further investigations in vivo.
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله | Achmad Lefi
Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Airlangga-Dr. Soetomo General Hospital, Surabaya, Indonesia.


| Denisa Asmarani
Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Airlangga-Dr. Soetomo General Hospital, Surabaya, Indonesia.


| Budi Dharmadjati
Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Airlangga-Dr. Soetomo General Hospital, Surabaya, Indonesia.


| Denny Suwanto
Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Airlangga-Dr. Soetomo General Hospital, Surabaya, Indonesia.


| Mahendra Saputra
Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Airlangga-Dr. Soetomo General Hospital, Surabaya, Indonesia.


| Vemaniarti Pravitasari
Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Airlangga-Dr. Soetomo General Hospital, Surabaya, Indonesia.


| Faizal Anandita
Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Airlangga-Dr. Soetomo General Hospital, Surabaya, Indonesia.
نشانی اینترنتی https://jthc.tums.ac.ir/index.php/jthc/article/view/2091
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات